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Abstract
Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor
(EGFR)–directed antibody (Ab) therapy. However, themechanisms bywhich constitutively activated KRAS (KRASG12V) impairs effector
mechanisms of EGFR-Abs are incompletely understood. Here, we established isogenic cell line models to systematically investigate
the impact of KRASG12V on tumor growth in mouse A431 xenograft models as well as on various modes of action triggered by
EGFR-Abs in vitro. KRASG12V impaired EGFR-Ab–mediated growth inhibition by stimulating receptor–independent downstreamsignal-
ing. KRASG12V also rendered tumor cells less responsive to Fc-mediated effector mechanisms of EGFR-Abs—such as complement-
dependent cytotoxicity (CDC) and Ab-dependent cell-mediated cytotoxicity (ADCC). Impaired CDC and ADCC activities could
be linked to reduced EGFR expression in KRAS-mutated versus wild-type (wt) cells, which was restored by small interfering RNA
(siRNA)–mediated knockdown of KRAS4b. Immunohistochemistry experiments also revealed lower EGFR expression in KRAS-
mutated versus KRAS-wt harboring CRC samples. Analyses of potential mechanisms by which KRASG12V downregulated EGFR
expression demonstrated significantly decreased activity of six distinct transcription factors. Additional experiments suggested the
CCAAT/enhancer-binding protein (C/EBP) family to be implicated in the regulation of EGFR promoter activity in KRAS-mutated tumor
cells by suppressing EGFR transcription through up-regulation of the inhibitory family member C/EBPβ–LIP. Thus, siRNA-mediated
knockdown of C/EBPβ led to enhanced EGFR expression and Ab-mediated cytotoxicity against KRAS-mutated cells. Together,
these results demonstrate that KRASG12V signaling induced C/EBPβ–dependent suppression of EGFR expression, thereby impairing
Fc-mediated effector mechanisms of EGFR-Abs and rendering KRAS-mutated tumor cells less sensitive to these therapeutic agents.
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Introduction
The epidermal growth factor receptor (EGFR) is among the most
widely expressed tumor-related antigens [1] and is successfully targeted
in patients by both tyrosine kinase inhibitors (TKIs) and monoclonal
antibodies (mAbs) [2–4]. For the last years, important progress has
been made in identifying molecular biomarkers that predict response
or resistance to EGFR inhibitors in colorectal cancer (CRC) [5]. Re-
sistance to EGFR inhibitors has been associated with activating muta-
tions of KRAS [6–9] and other mediators of downstream signaling
such as v-raf murine sarcoma viral oncogene homolog B1 (B-RAF )
[6,8], phosphoinositide-3-kinase, phosphatase and tensin homolog
(PTEN), and others [5,10]. Nevertheless, the expression of the EGFR
ligands epiregulin and amphiregulin was associated with improved
response rates [11]. However, the molecular mechanisms underlying
these clinical observations are incompletely understood.
KRAS belongs to the family of three RAS proto-oncogenes encoding
five small monomeric guanosine triphosphatases (GTPases) (NRAS,
HRAS1, HRAS2, KRAS4a, and KRAS4b). RAS proteins have intrinsic
GTPase activity—enabling them to switch between inactivated, guano-
sine diphosphate-bound and activated, GTP-bound states. Thereby, they
mediate ligand-induced signal transduction by receptor tyrosine kinases
like the EGFR [12,13]. Importantly, distinct somatic point mutations
in RAS genes (commonly restricted to codon 12, 13, or 61) turn these
proto-oncogenes into oncogenes by affecting their intrinsic GTPase
activity—thereby forcing constitutive activation of RAS proteins and
stimulating downstream signaling pathways such as mitogen-activated
protein kinases (MAPKs) and phosphoinositide-3-kinase [14].
Recent studies investigated the frequency of RAS gene point muta-
tions in distinct solid tumors and demonstrated the KRAS gene to
be more frequently mutated than NRAS or HRAS—mainly in tu-
mors of the pancreas, the lung, or the colon [15]. Furthermore, clinical
trials studying therapeutic efficacy of EGFR-directed antibodies like
cetuximab or panitumumab showed that patients experiencing KRAS-
mutated colorectal tumors do not respond to these agents [6,8,9]. This
led to label restrictions for EGFR-Abs in CRC patients bearing wild-
type (wt) KRAS tumors [16].
EGFR-Abs are able to elicit distinct effector mechanisms for tumor
cell destruction: Fab-mediated effects comprise inhibition of ligand-
binding or tumor cell growth, apoptosis induction, as well as EGFR
down-modulation, whereas Fc-mediated effector mechanisms are trig-
gered through the Fc region by binding either complement compo-
nent C1q to induce complement-dependent cytotoxicity (CDC) or
Fc receptors on effector cells to trigger Ab-dependent cell-mediated
cytotoxicity (ADCC) or phagocytosis [4]. Both Fab- and Fc-mediated
effector mechanisms have been suggested to be important for thera-
peutic outcome of EGFR-Abs [3]—with recent studies demonstrating
a strong impact of Fc-mediated effector mechanisms on the efficacy
of EGFR-Abs [17]. Furthermore, distinct genetic polymorphisms
that determine the binding affinity and ADCC efficacy for FcγRIIa
(131 H/R) and FcγRIIIa (158 V/F) have been described and were
linked to clinical outcome of therapeutic EGFR-Abs in metastatic
CRC (mCRC) [18]. Considering these findings, it might be hypoth-
esized that Fc-mediated mechanisms of EGFR-Abs play important
roles in tumor cell destruction. However, whether oncogenic muta-
tions in the KRAS gene directly affect ADCC or CDC activity, as
described for Fab-mediated effector mechanisms [19], has—to our
knowledge—not been previously investigated.
In this study, we observed that oncogenic KRASG12V signaling is
accompanied by down-regulation of EGFR transcript and protein levels
in a C/EBPβ–dependent manner. Decreased EGFR cell surface expres-
sion was accompanied by diminished ADCC as well as CDC and
might in part explain the lack of efficacy of EGFR-Abs in the therapy
for KRAS-mutated tumors.
Materials and Methods
Blood Donors
Experiments reported here were approved by the Ethics Committee of
the Christian-Albrechts-University, Kiel, Germany, in accordance with
the Declaration of Helsinki. Blood donors were randomly selected from
healthy volunteers, who gave written informed consent before analyses.
Cell Lines and Antibodies
Human epidermoid carcinoma cell line A431 (DSMZ, Braunschweig,
Germany) was kept in RPMI 1640 medium, whereas A549 (ECACC,
Salisbury, UK), HCT-116 (DSMZ), and A1207 (originally established
by Dr Aaronson, National Cancer Institute, National Institutes of
Health, Bethesda, MD [20]) cell lines were cultivated in Dulbecco
modified Eagle medium. Cell culture media were supplemented with
10% (vol/vol) heat-inactivated fetal calf serum, 100 U/ml penicillin,
and 100 μg/ml streptomycin.
EGFR-directed antibodies used in this study: C225 (cetuximab;
chimeric immunoglobulin [Ig] G1; Erbitux; Merck, Darmstadt,
Germany), 2F8 (zalutumumab; human IgG1; Genmab, Utrecht, the
Netherlands), and HuMab 003 (human IgG1; Genmab). VH and VL
regions of the humanized EGFR-directed IgG1 antibody (Ab) H425
(source: PCT application WO 92/15683) were cloned into an expres-
sion vector harboring an IgG1 Fc variant with amino acid exchanges
K326A and E333A in the CH2 domain (=H425-E3), known to
increase C1q binding [21]. An irrelevant human IgG1 Ab (Alpha
Diagnostic Intl. Inc, San Antonio, TX) or an irrelevant mouse Ab
served as control antibodies.
Plasmid Construction
Expression plasmid for KRAS4bG12V was generated as described pre-
viously [19]. The wt promoter region of EGFR, spanning nucleotides
−620 to −1000, as well as a mutated version lacking the predicted
C/EBP binding site (ATTGG and GCAAT) were synthesized by
Entelechon GmbH (Regensburg, Germany). For bioinformatic analy-
sis of the EGFR promoter sequences regarding C/EBP binding, the
TFSEARCH software (Computational Biology Research Center,
AIST, Japan http://www.cbrc.jp/research/db/TFSEARCH.html) was
used. The promoter regions were inserted into the pGL3Enhancer
vector (Promega, Madison, WI) by using the restriction sites KpnI
and BglII. The resulting constructs were termed pGL3E-EGFR prom
wt and pGL3E-EGFR prom mut.
Immunoprecipitation
Activated RASGTP was precipitated as previously described [19].
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Total RNA was isolated using the RNeasy kit (Qiagen, Inc, Valencia,
CA) following the manufacturer’s instructions. Reverse transcription
was performed by using iScript complementary DNA (cDNA) Syn-
thesis Kit (Bio-Rad Laboratories, Munich, Germany). The expression
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of EGFR, KRAS4b, β-actin, or G3PDH was assayed using standard
semiquantitative reverse transcription–polymerase chain reaction (RT-
PCR) procedures and following sequence specific primers: EGFR sense
5′-GTGAGTTGATCATCGAATTCTC-3′ and antisense 5′-CATGC-
TCCAATAAATTCACTGC-3′, KRAS4b sense 5′-ATGACTGAATA-
TAAACTTGTGG-3′ and antisense 5′-CCATCTTTGCTCATCTT-
TTC-3′, β-actin sense 5′-GATGGTGGGCATGGGTCAG-3′ and
antisense 5′-CTTAATGTCACGCACGATTTCC-3′, and G3PDH
sense 5′-TGAAGGTCGGAGTCAACGGATTTGGT-3′ and anti-
sense 5′-CATGTGGGCCATGAGGTCCACCAC-3′.
SDS-PAGE and Immunoblot Analysis
Whole protein extracts were prepared by lysing cell pellets in dena-
turing lysis buffer containing 1% SDS, 10 mM Tris (pH 7.4), and
1% protease inhibitor mixture (Complete Protease Inhibitor Cocktail;
Roche Applied Science, Mannheim, Germany). Nuclear protein ex-
tracts were prepared from 1 × 107 cells according to the manufacturer’s
instructions using the Nuclear Extraction Kit (Signosis, Inc, Sunnyvale,
CA). Ten micrograms of protein extracts was separated by denaturing
SDS-PAGE and transferred onto polyvinylidene fluoride membranes
(Millipore, Billerica, MA). After blocking, membranes were probed
with specific primary Ab, washed, and incubated with HRP-conjugated
IgG as secondary Ab. Proteins were visualized by chemiluminescence
(Thermo Fisher Scientific, Rockford, IL). To determine even transfer
and equal loading, membranes were stripped and reprobed with anti-
bodies specific for nonphosphorylated protein or β-actin/G3PDH.
Immunofluorescence Microscopy
A431-control-vector or A431-KRASG12V cells were seeded on sterile
coverslips. Next day, cells were washed, fixed in 4% paraformaldehyde–
phosphate-buffered saline and blocked for 1 hour in 0.75% bovine serum
albumin–phosphate-buffered saline. Cells were stained for EGFR cell sur-
face expression using C225 (2 μg/ml) and goat phycoerythrin-conjugated
F(ab′)2 fragments against human IgG (Jackson ImmunoResearch,
Suffolk, England) as secondary Ab. 4′,6-diamidino-2-phenylindole
(DAPI) was used for DNA counterstaining. Coverslips were mounted
onto glass slides and examined using a Zeiss AxioImager.Z1 apotome
fluorescence microscope and the AxioVision Imaging software (Carl
Zeiss MicroImaging, Inc, Thornwood, NY).
Flow Cytometric Analyses
For indirect immunofluorescence, cells were stained as described pre-
viously [19]. Relative fluorescence intensity (RFI) was calculated with the
following formula: mean fluorescence intensity (MFI) EGFR-Ab / MFI
control Ab. Quantitative surface EGFR expression was determined
using a murine EGFR-Ab, a murine IgG1 Ab as a control Ab, and
the QIFIKIT (Dako, Glostrup, Denmark) according to the manufac-
turer’s instructions except for using PerCP-conjugated (Fab′)2 fragments
(Jackson ImmunoResearch, England). Samples were analyzed on a flow
cytometer (Epics Profile; Beckman Coulter, Fullerton, CA).
Determination of Viable Cell Mass (MTS Assay)
The CellTiter 96 nonradioactive cell proliferation assay was performed
using A431-control-vector or A431-KRASG12V cells (5 × 103 cells
per well in 96-well microtiter plate) according to the manufacturer’s
instruction (Promega).
Cytotoxicity Assays
As previously described, human effector cells such as peripheral blood
mononuclear cells (MNCs), NK cells, monocytes, or polymorpho-
nuclear cells (PMNs) were isolated from peripheral blood drawn from
healthy volunteers and assayed in ADCC experiments [22].
CDC assays were performed as described in Dechant et al. [20]
using freshly drawn human plasma (25% vol/vol), anticoagulated with
100 U/ml heparin, and the Ab H425-E3 alone or HuMab 003 (final
concentration of 5 μg/ml) in combination with C225, 2F8, or control
Ab at various concentrations was added to microtiter plates.
Percentage of cytotoxicity was calculated using the following formula:
percent specific lysis = [(experimental cpm − basal cpm) / (maximal
cpm − basal cpm)] × 100.
Small Interfering RNA–Mediated Knockdown Experiments
Cells were seeded at a density of 1 × 105/well in six-well plates. Next
day, transfection of small interfering RNA (siRNA) was carried out using
Lipofectamine2000 (Invitrogen, Carlsbad, CA). For all procedures,
standard protocols were used according to the manufacturers’ manuals.
Synthetic siRNAs targeting KRAS4b or C/EBPβ were purchased
from Applied Biosystems/Ambion (Carlsbad, CA). Target sequences
were as follows: KRAS siRNA 1 (ID s7939) sense 5′-CUAUGGUC-
CUAGUAGGAAAtt-3′ and antisense 5′-UUUCCUACUAGGACC-
AUAGgt-3′; KRAS siRNA 2 (ID s7940) sense 5′-GCCUUGACGA-
UACAGCUAAtt-3′ and antisense 5′-UUAGCUGUAUCGU-
CAAGGCac-3′; and C/EBPβ (ID s2892) sense 5′-GGCCCUGAGU-
AAUCGCUUAtt-3′ and antisense 5′-UAAGCGAUUACUCAGGG-
CCcg-3′. As a control, unspecific siRNA Negative Control 1 (Applied
Biosystems/Ambion) was used.
Transcription Factor Activity Profiling Assay
Analysis of activity of 48 transcription factors (TFs) was performed
according to the manufacturer’s instructions using the TF Activation
Profiling Plate Array I (Signosis). Ten micrograms of nuclear protein
extracts was assayed per sample. TFs were selected by the fold-change
method (≤−1.5 or ≥1.5) and the rank sum difference (≥7) of A431-
KRASG12V cells compared with A431-control-vector cells.
Dual Luciferase Reporter Gene Assay
To quantify C/EBP activation, a dual-luciferase reporter gene assay
(Promega) was used according to the manufacturer’s instructions.
A431-control-vector or A431-KRASG12V cells were seeded at a density
of 1.5 × 104 cells per well and grown until 50% to 70% confluence
on 96-well plates. The next day, cells were transfected with 120 ng/
well of cis-reporting pC/EBP_Luc plasmid (Agilent Technologies,
La Jolla, CA), 40 ng/well of pRL-TK (Promega) reference plasmid,
and 40 ng/well of pSec empty vector for 24 hours. C/EBP activation
was calculated as relative light units (RLU) by normalizing firefly
luciferase activity to reference activity (Renilla luciferase). For quantifica-
tion of EGFR promoter transactivation, A431-control-vector or A431-
KRASG12V cells were seeded at a density of 1.5 × 104 cells per well
and grown until 50% to 70% confluence on 96-well plates. Next day,
cells were transfected with 40 ng/well of pGL3E, pGL3E-EGFR prom
wt, or pGL3E-EGFR prom mut and 20 ng/well of pRL-TK reference
plasmid for 48 hours. Dual luciferase assay was performed using the
Dual-Luciferase Reporter Assay System (Promega) andTecanGeniosPro
microplate reader (Tecan Trading AG, Crailsheim, Germany).
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TaqMan Real-time PCR
For real-time PCR experiments, cDNA derived from four colorectal
carcinoma biopsy samples (nos. 3-6: no. 3 = human colon 2 matched
cDNA pair [Takara Bio Europe/Clontech, Saint-Germain-en-Laye,
France] and nos. 4-6 = RNA [AMS Biotechnology Europe Ltd, Bioggio-
Lugano, Switzerland]) as well as two biopsy samples from normal colon
tissue (nos. 1 and 2: no. 1 = human MTC panel II [Takara Bio Europe/
Clontech] and no. 2 = human colon 2 matched cDNA pair [Takara
Bio Europe/Clontech]) were included in this study. All six samples were
analyzed by Sanger sequencing experiments regarding KRAS status
(Figure 7A).
EGFR messenger RNA (mRNA) transcript levels were measured
using quantitative real-time PCR. cDNA was arrayed on 384-well plates
using the expression assayHs01076078_m1 (Applied Biosystems, Foster
Figure 1. KRASG12V-transfected cells display increased MAPK activation and cell growth. (A) Human KRAS4b in complex with GTP. The
presented models illustrate the position of the G12V mutation, which is located in the GTP-binding pocket—ranging from amino acids
10 to 16. Human KRAS4b crystal structure pdb file 2PMX. The picture was generated using three-dimensional Mol Viewer software (a
component of Vector NTI Advance 10.3.0; Invitrogen): top (I) and bottom (II) views. Blue indicates backbone (upper panels) or calculated
surface (lower panels); red, GTP analog; green, amino acid substitution G12V analyzed in the present study. (B) To ensure that over-
expression of KRASG12V is accompanied by expression of constitutively activated KRAS, activated RAS was precipitated and analyzed
by SDS-PAGE and immunoblot analysis against RAS and Myc-tag (left panel). Whole-protein lysates served as expression control for
endogenous RAS and transfected KRASG12V (right panel). (C) Overexpression of KRASG12V was accompanied by constitutive activation
of MAPK p44/42. Whole protein extracts were prepared from A431-control-vector or A431-KRASG12V cells and analyzed by SDS-PAGE
and immunoblot analysis against phosphorylated and unphosphorylated p44/42. Immunoblot analysis against G3PDH served as loading
control. (D) Overexpression of oncogenic KRASG12V induced enhanced cell growth rate in 72 hours MTS assays. Data are presented
as mean ± SEM of three independent experiments. *P ≤ .05 for A431-KRASG12V cells versus A431-control cells. (E) Overexpression of
oncogenic KRASG12V induced enhanced tumor growth in vivo. Data for A431-KRASG12V represent an average and SD (n = 5). Data for
A431 cells represent an average and 95%CI (n=53) and calculated as described in theMaterials andMethods section. The A431-KRASG12V
growth rate lies outside the 95% CI of the A431 cells, indicating that the difference is significant.
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City, CA) on the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) according to the manufacturer’s instructions. Rela-
tive transcript levels were determined using G3PDH (Hs99999905_m1)
as the endogenous control gene.
Immunohistochemical Analysis of Human Colorectal
Carcinoma Samples
Paraffin-embedded human tumor samples were provided by the
Pathology “Nordhessen,” Kassel, Germany, in accordance with local
ethical guidelines. KRAS codon 12 mutation status was determined
by melting point analysis using the cobas z 480 system (Roche).
EGFR-immunohistochemistry (IHC) was performed using the EGFR
pharmDx kit on the Link 48 Autostainer (both by Dako) according
to the manufacturer’s protocol. Slices were cut at 4 μm, and incuba-
tion times were as follows: peroxidase blocking, 5 minutes; proteinase
K digestion, 5 minutes; primary Ab (clone 2-18C9), 30 minutes; HRP-
conjugated secondary Ab, 30 minutes; Tris-buffered saline supple-
mented with 0.05% (vol/vol) Tween-20 (TBST) 0.05%, 5 minutes;
DAB chromogen, 5 minutes; hematoxylin counterstain, 5 minutes.
Intensity evaluation by IHC scoring (score 0-300) was done as de-
scribed in various studies on EGFR expression [23,24]. By integra-
tion of the data relating to the intensity and frequency of staining,
the IHC score was calculated with the formula: 1 × (percentage of
cells staining weakly [1+]) + 2 × (percentage of cells staining moder-
ately [2+]) + 3 × (percentage of cells staining strongly [3+]). To avoid
bias, the scoring pathologist was blinded about the KRAS status of
the samples.
Mouse Tumor Xenograft Models
SCID mice (C.B.-17/IcrCrl-scid/scid) were purchased from Charles
River (Maastricht, the Netherlands). All experiments were performed
with 8- to 12-week-old female mice. Mice were housed in a barrier
unit of the Utrecht University Central Laboratory Animal Facility
(Utrecht, the Netherlands) and kept in filter-top cages with water
and food provided ad libitum. Mice were checked at least twice a
week for clinical signs of disease and discomfort. All experiments were
approved by the Utrecht University animal ethics committee. Sub-
cutaneous tumors were induced by subcutaneous inoculation of 5 ×
106 A431 cells or 5 × 106 A431-KRAS4bG12V cells in the right flank
of mice. Tumor volumes were calculated from digital caliper measure-
ments as 0.52 × length × width2 (mm3). For the A431 cells, the 95%
confidence interval (CI) of the tumor development was calculated over
seven independent experiments, comprising a total of 53 mice. Tumor
growth data from each mouse were fit to a monoexponential curve, de-
termined by y0 and k. Subsequently, the average y0, k, and the 95% CI
were calculated. These data were plotted against the average tumor
growth of 5 × 106 A431-KRAS4bG12V cells in five mice.
Data Processing and Statistical Analyses
Data are displayed graphically and were statistically analyzed using
GraphPad Prism 4.0 (GraphPad Software, La Jolla, CA). Curves were
Figure 2. Oncogenic KRAS renders cells unresponsive to EGF stimulation and impairs proliferation inhibition by EGFR mAb. (A) A431
cells were seeded into 96-well microtiter plates, incubated in the presence or absence of rhEGF (left panel, 0.001-100 ng/ml for
72 hours; right panel, 10 ng/ml for 24-72 hours), and analyzed by MTS assays. Data are presented as mean ± SEM from at least three
independent experiments. *P ≤ .05 stimulated cells versus unstimulated cells, #P ≤ .05 for A431-KRASG12V cells versus A431-control-
vector cells. (B) EGFR Ab-mediated growth inhibition was impaired in KRASG12V-transfected cells. A431 cells were incubated in the
presence or absence of C225 (left), 2F8 (middle), or control Ab (right; 0.0128-40 μg/ml). After 72 hours, cells were analyzed by MTS
assays. Data are presented as mean ± SEM from at least three independent experiments. *P ≤ .05 C225/2F8 versus control Ab, #P ≤
.05 for A431-KRASG12V cells versus A431-control-vector cells.
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Figure 3. Tumor cell lysis mediated by complement or ADCC is diminished in KRASG12V-transfected cells. For cytotoxicity experiments,
A431 control or KRASG12V cells were incubated with increasing concentrations of C225, 2F8 or control Ab and (A) NK cells (E/T ratio 10:1),
(B) monocytes (E/T ratio 40:1), (C) PMN (E/T ratio 80:1), or (D) plasma (25% vol/vol). For CDC experiments, a second noncompeting EGFR-
Ab was added at 5 μg/ml. Data are presented as mean ± SEM from at least three independent experiments with different donors. *P≤ .05
C225/2F8 versus control Ab, #P ≤ .05 for A431-KRASG12V cells versus A431-control-vector cells.
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fitted using a nonlinear regression model with a sigmoidal dose response
(variable slope). Statistical significance was determined by the Student’s
t test (paired, 2-tailed; Figures 1C , 4C , and 5B) or by the two-way
analysis of variance repeated-measures test with the Bonferroni post test
(Figures 2, 3, 4B, 5D, and 6). The respective results were displayed as
mean ± SEM of at least three independent experiments. P values were
calculated, and null hypotheses were rejected when P ≤ .05.
Densitometric analysis of immunoblots received from the detec-
tion of proteins by chemiluminescence was performed using the non-
commercial software ImageJ (http://rsb.info.nih.gov/ij/).
Figure 4. EGFR expression is downregulated in KRASG12V-transfected cells. (A) EGFR transcripts were downregulated in A431-KRASG12V
cells (upper panel). Total RNA was isolated from A431-control-vector and A431-KRASG12V cells. mRNA expression of EGFR and G3PDHwas
assayed by RT-PCR and visualized by agarose gel electrophoresis. Diminished EGFR mRNA expression was associated with lower EGFR
protein levels (lower panel). Membranous protein extracts were prepared from A431-control-vector and A431-KRASG12V cells. Protein
extracts were separated by SDS-PAGE and immunoblotted against EGFR. Loading of equal protein amounts was controlled with β-actin
Ab. (B) EGFR protein expression is also downregulated in A431 xenograft models. Whole protein extracts were prepared from explanted
A431 wt and A431-KRASG12V tumors, separated by SDS-PAGE and immunoblotted against EGFR and β-actin as the loading control. (C and
D) Diminished EGFR cell surface expression in A431-KRASG12V cells is reflected by lower C225 and 2F8 binding levels at Ab saturating
concentrations. (C) For indirect immunofluorescence, A431-control-vector and A431-KRASG12V cells were incubated with increasing con-
centrations of C225, 2F8 or a control Ab and stained with polyclonal rabbit PerCP-conjugated F(ab′)2 fragments against human IgG. Each
data point represents the RFI of C225 or 2F8 versus control IgG1 Ab. (D) A431-control-vector cells or A431-KRASG12V cells were fixed,
incubated with C225 and goat phycoerythrin-conjugated F(ab′)2 fragments against human IgG and counterstained using DAPI. (E) Quanti-
tative analyses of EGFR molecules per cell were performed using QIFIKIT. Cells were incubated with a murine EGFR or control Ab and
stained with goat PerCP-conjugated F(ab′)2 fragments against murine IgG. (F) siRNA-mediated knockdown of KRAS4b in nontransfected
A431 cells. Cells were transfected with two different KRAS4b-specific or control siRNA. After 72 hours, cDNA was prepared, and mRNA
expression of KRAS4b and G3PDH was assayed by RT-PCR. (G and H) Knockdown of KRAS4b induced up-regulation of EGFR. A431-
KRASG12V cells were transfected with KRAS4b-specific or control siRNA for up to 72 hours and analyzed by RT-PCR (G) and Western
blot (H). Down-regulation of KRAS4b mRNA level (G) as well as RAS protein level (H) was detected, whereas EGFR mRNA and protein
expressions were time-dependently upregulated. Means ± SEM of three independent experiments are presented in C and E. *P ≤ .05
for A431-KRASG12V cells (C225) versus A431-control cells (C225); #P ≤ .05 for A431-KRASG12V cells (2F8) versus A431-control cells (2F8).
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Results
Constitutively Activated KRASG12V Stimulates MAPK
p44/42 and Increases Viable Cell Mass
Intrinsic GTPase activity of KRAS4b facilitates the switch be-
tween activated (binding of GTP) and inactivated state (binding of
guanosine diphosphate). The amino acid substitution G12V impairs
GTPase activity—leading to the constitutive activation of KRAS4b
(Figure 1A). To ensure that overexpression of oncogenic KRAS4bG12V
in A431 cells led to constitutive activation of KRAS and downstream
signaling pathways, RAS and MAPK p44/42 activation was analyzed
by immunoprecipitation and immunoblot experiments. The expression
of exogenous KRAS4bG12V led to constitutive activation of KRAS4bG12V
(Figure 1B), which triggered enhanced phosphorylation of MAPK p44/
Figure 5. The family of C/EBP transcription factors displays decreased activity in A431-KRASG12V cells and is involved in the suppres-
sion of the EGFR promoter. (A) Table providing an overview of significantly regulated TF in A431-KRASG12V cells versus A431-control-
vector cells determined by TF activity profiling assay. (B) A reporter gene assay for C/EBP TF family activation revealed decreased
C/EBP activation in A431-KRASG12V cells. A431-control-vector or A431-KRASG12V cells were cotransfected with a C/EBP–dependent
luciferase reporter gene construct and a pRL-TK Renilla plasmid for normalization. Luciferase activity was measured and presented
as RLU. (C) Model of EGFR promoter constructs. EGFR promoter sequences representing wt or mutated sequences are presented.
The mutated EGFR promoter sequence lacks putative C/EBP DNA-binding sites. For generation of EGFR promoter constructs, a
sequence of 381 nucleotides (−620 to −1000 nt; presented are −620 to −754 nt) upstream of the EGFR coding sequence was
inserted into the Firefly luciferase reporter gene plasmid pGL3Enhancer. The resulting constructs were termed EGFR prom wt
and EGFR prom mut. (D) The family of C/EBP TF inhibited EGFR promoter activity. Dual luciferase assays with reporter gene con-
structs representing the wt or mutated EGFR promoter were used to quantify promoter activity. A431-control-vector or A431-
KRASG12V cells were transfected with EGFR promoter constructs and a pRL-TK Renilla plasmid for normalization. Luciferase activity
was measured and calculated as RLU. Data are presented as mean ± SEM of triplicate wells from at least three independent
experiments. *P ≤ .05.
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42 (Figure 1C ) that has been also detected in KRAS-mutated CRC
cell lines such as SW480 and HCT-116 (data not shown). Further-
more, A431-KRASG12V cells displayed significantly increased cell
growth rates when compared with A431-control-vector cells in vitro
(∼45% increase; Figure 1D). The growth rate of A431-KRASG12V cells
in vivo as a xenograft was also significantly increased compared with
A431-WT cells (average A431-KRASG12V growth rate lies outside the
95% CI of A431-WT; Figure 1E).
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KRASG12V Prevents EGF-Induced Reduction of Cell Viability
and Impairs Growth Inhibition by EGFR Antibodies
A431 cells have been shown to undergo cell death when stimulated
with high concentrations of EGF [25]. To analyze whether constitutively
activated KRAS signaling in A431-KRASG12V cells impaired ligand-
induced signal transduction, A431-control-vector and A431-KRASG12V
cells were stimulated with recombinant human (rh) EGF at increasing
concentrations (0.001-100 ng/ml; 72 hours), for different time intervals
(24, 48, and 72 hours; 10 ng/ml), or were left untreated (Figure 2A).
After incubation, viable cell mass was analyzed by MTS assay. Viable cell
mass was significantly reduced by EGF stimulation in a concentration-
and time-dependent manner in A431-control-vector cells (∼70% at
100 ng/ml, 72 hours) but not in A431-KRASG12V cells.
Owing to the observed unresponsiveness of A431-KRASG12V cells to
EGF-induced cell death at high EGF concentrations, further experi-
ments were performed to study the impact of proliferative signaling cas-
cades triggered by oncogenic KRAS on EGFR-Ab–mediated cell growth
inhibition. Hence, cells were incubated for 72 hours in the presence
or absence of increasing concentrations (0-40 μg/ml) of C225, 2F8, or
an irrelevant control human IgG1 Ab and analyzed by MTS assays
(Figure 2B). Whereas growth of A431-control-vector cells was signifi-
cantly inhibited by C225 (∼25%) or 2F8 (∼25%) in a concentration-
dependent manner when compared with control Ab-treated cells, only
modest—albeit also statistically significant—inhibition was detected for
A431-KRASG12V cells by C225 (∼13%) or 2F8 (∼11%).
ADCC as well as Complement-Mediated Tumor Cell Lysis Is
Diminished in A431 KRASG12V Cells
In mouse A431 wt and KRASG12V xenograft models, also used in
the present study, activation of ADCC has been proposed to be an
important mechanism of action of EGFR-mAb such as zalutumumab
(2F8) in early stages of tumor development [26]. However, the rela-
tive contribution of different effector cell populations remains to be
unraveled. Therefore, A431-KRASG12V and A431-control-vector cells
were analyzed regarding Fc-mediated effector mechanisms induced
by C225 and 2F8. ADCC experiments were performed with isolated
NK cells, monocytes, or PMN effector cells. A slight but signifi-
cant (only for 2F8) decrease in ADCC activity was detected with
NK cells (A431-KRASG12V maximum lysis at 10 μg/ml [ML]:
C225≈ 38%, 2F8≈ 34%; A431-control-vector cells ML: C225≈
45%, 2F8≈ 46%; Figure 3A). Furthermore, significantly diminished
monocyte- and PMN-mediated tumor cell lysis was observed in A431-
KRASG12V cells (Figure 3, B and C ; ML monocytes: C225 ≈ 23%,
2F8 ≈ 18%; ML PMN: C225 ≈ 14%, 2F8 ≈ 18%) when
compared with A431-control-vector cells (ML monocytes: C225 ≈
35%, 2F8≈ 35%; ML PMN: C225≈ 25%, 2F8≈ 38%; Figure 3,
B and C ). A431-KRASG12V cells also displayed significantly impaired
cell lysis compared with A431-control-vector cells in CDC experi-
ments with C225 and 2F8 using a second noncompeting EGFR-
mAb and human plasma as effector source. Whereas strong CDC
activity was induced in A431-control-vector cells by C225 (ML
C225 ≈ 35%) and 2F8 (ML 2F8 ≈ 26%), only low killing of
A431-KRASG12V cells was observed (ML C225≈ 11%; 2F8≈ 6%;
Figure 3C ). Because CDC activity depends on the expression of
complement-inhibitory proteins like CD46 or CD59, we quantified
cell surface expression of these molecules on A431-KRASG12V and
A431-control-vector cells. In A431-KRASG12V cells, significantly
lower levels of CD46 and CD59 cell surface expression (CD46
0.8 × 105 ± 0.02 × 105 molecules per cell; CD59 3.1 × 105 ±
0.15 × 105 molecules per cell) were detected compared with A431-
control-vector cells (CD46 1.9 × 105 ± 0.43 × 105 molecules per
cell; CD59 4.7 × 105 ± 0.15 × 105 molecules per cell; Figure W1).
Hence, it may be concluded that diminished CDC activity in A431-
KRASG12V cells is not the result of enhanced expression of complement-
inhibitory proteins.
Expression of Oncogenic KRASG12V Is Accompanied by
Down-regulation of EGFR
KRAS is an established downstream mediator of EGFR signal
transduction and overexpression of constitutively activated mutant
(KRASG12V) hampered cell growth inhibition as well as ADCC and
CDC induced by EGFR-Ab. Because Ab-mediated cytotoxicity cor-
related with antigen cell surface expression levels [27], we investigated
whether expression of EGFR was altered in KRASG12V-transfected
cells. Interestingly, EGFR transcript and protein levels were down-
regulated in A431-KRASG12V cells when compared with A431-control-
vector cells (Figure 4A). As shown in Figure 4B, decreased EGFR
expression was accompanied by decreased binding of EGFR-Abs.
Significantly lower fluorescence signal intensities for C225 and 2F8
were detected by indirect immunofluorescence in A431-KRASG12V
Figure 6. C/EBPβ is induced by oncogenic KRAS and is involved in the regulation of EGFR expression. (A) Expression of oncogenic
KRAS was accompanied by regulation of C/EBP TF family members’ nuclear protein expression. Nuclear protein fractions were pre-
pared from A431-KRASG12V and A431-control-vector cells. Ten micrograms of protein extracts was separated by SDS-PAGE and
immunoblotted against C/EBPβ/δ//γ/ζ or β-actin—serving as a protein loading control. Arrows indicate the predicted molecular weights
of respective TF. One of several independent experiments is presented. (B) Densitometric analysis of C/EBPβ specific immunoblot pres-
ented in Awas performed using ImageJ software. (C) C/EBPβ expression was controlled by KRAS. A431-KRASG12V cells were transfected
with 25 nM KRAS4b-specific or control siRNA for 72 hours. Nuclear protein extracts were separated by SDS-PAGE and immunoblotted
against C/EBPβ. (D and E) RNAi-induced knockdown of C/EBPβ enhanced EGFR expression. A431-KRASG12V (upper panel) or A549 (lower
panel) cells were transfected with 25 nM control siRNA or C/EBPβ siRNA. After 24 and 48 hours, cDNA was prepared and mRNA
expression of EGFR, β-actin, and G3PDH was assayed by RT-PCR. (F) Whole protein extracts of A431-KRASG12V cells, transfected with
C/EBPβ–specific siRNA, were prepared after 48 hours of transfection, separated by SDS-PAGE and immunoblotted against C/EBPβ,
EGFR, and β-actin. (G) RNAi-induced knockdown of C/EBPβ enhanced EGFR-directed Ab-mediated cytotoxicity. A431-control-vector or
A431-KRASG12V cells were transfected with 25 nM control siRNA or C/EBPβ–specific siRNA for 48 hours. Plasma served as effector
source in 51Cr release assays using H425-E3 Ab (0-1 μg/ml). (G and H) A431 KRASG12V cells were transfected with a plasmid coding
for human EGFR for 24 hours by lipofection. After transfection, cells were harvested and either analyzed by SDS-PAGE and immunoblot
experiments (G) or assayed in 3 hours of 51Cr release assays using plasma and the indicated antibodies (both at 1 μg/ml; H). Data are
presented as mean ± SEM of triplicate wells from at least three independent experiments with different blood donors. *P ≤ .05.
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cells (RFIC225; 200 μg/ml = 13.7; RFI2F8; 200 μg/ml = 13.9) compared with
A413-control-vector cells (RFIC225: 200 μg/ml = 89.1; RFI2F8: 200 μg/ml =
95.3; Figure 4B). To determine EGFR cell surface expression, A431-
KRASG12V or A431-control-vector cells were examined by immuno-
fluorescence microscopy (Figure 4C ) as well as by quantitative flow
cytometry (Figure 4D). A significant decrease in EGFR molecules
per cell (∼50%) was detected in KRASG12V-transfected cells (1.4 ×
106 ± 0.2 × 106 molecules per cell) compared with control cells (2.8 ×
106 ± 0.1 × 106 molecules per cell; Figure 4D). To confirm results
received from A431 cells in another cell line model, A1207 cells were
stably transfected with KRAS4bG12V (Figure W2A). Quantitative flow
cytometry revealed statistically significant down-regulation of EGFR
cell surface expression in A1207-KRASG12V cells (1.2 × 106 ± 0.2 ×
106 molecules per cell) compared with control cells (2.8 × 106 ± 0.2 ×
106 molecules per cell; Figure W2B).
To further elucidate the impact of oncogenic KRAS on EGFR expres-
sion in A431-KRASG12V cells, RNAi-induced knockdown experiments
using KRAS4b-specific siRNAs were performed. A decrease in KRAS4b
mRNA expression was detected after transfection of A431 cells for
72 hours with two different KRAS4b-specific siRNAs, whereas no reg-
ulation was observed using a negative control siRNA (Figure 4E). In
contrast to control siRNA-transfected A431-KRASG12V cells, RNAi-
induced knockdown of KRAS4b in A431-KRASG12V cells led to
time-dependent up-regulation of EGFR mRNA (Figure 4F) as well as
protein expression levels (Figure 4G).
Overexpression of KRASG12V Is Accompanied by the Inhibition
of C/EBP Family Activity
As demonstrated above, overexpression of KRASG12V in A431
cells led to down-regulation of EGFR transcription, which then
may impair Fab- and Fc-mediated effector mechanisms of EGFR-
mAb. To obtain a more profound insight into mechanisms leading
to the down-regulation of EGFR expression, activity of 48 TFs was
analyzed in A431-KRASG12V and A431-control-vector cells using a
TF activity profiling assay. Figure 5A represents data from 7 of 48
TFs that were significantly regulated (fold change ≥ 1.5 and ≤−1.5,
rank sum difference ≥ 7) in A431-KRASG12V cells when compared
with A431-control-vector cells. Among these, the C/EBP family of
TFs, AP2, and ATF2 were the most suppressed ones. On the basis
of these findings and previous studies, demonstrating a direct link
between oncogenic RAS and the C/EBP family member C/EBPβ
[28–31], C/EBP was chosen for further analyses. Confirmation of
TF activation analysis was obtained from a reporter gene assay for
C/EBP (Figure 5B). To further investigate whether the family of
C/EBP TFs regulates EGFR promoter activity and controls transcription
activity, luciferase reporter gene constructs harboring the wt EGFR
promoter sequence or a mutated EGFR promoter sequence that lacks
the C/EBP DNA-binding site were prepared (Figure 5C ). Dual lucifer-
ase assays with reporter gene constructs representing wt or mutated
EGFR promoter were performed and revealed significantly decreased
activity of the wt EGFR promoter in A431-KRASG12V cells (RLU =
12.56 ± 0.80) compared with A431-control-vector cells (RLU =
24.86 ± 2.87). In A431-KRASG12V cells, the mutated EGFR promoter
construct displayed significantly enhanced activity in comparison to the
wt EGFR promoter construct (RLUEGFR prom mut = 22.31 ± 3.95 vs
RLUEGFR prom wt = 12.56 ± 0.80), whereas no difference could be
observed between both constructs in A431-control-vector cells
(RLUEGFR prom mut = 24.15 ± 4.84 vs RLUEGFR prom wt = 24.86 ±
2.87; Figure 5D). Together, these data point to a C/EBP–dependent
suppression of EGFR promoter activity in A431-KRASG12V cells.
C/EBPβ Is a Suppressor of EGFR Transcription in
KRAS-Mutated Cells
The family of C/EBP TFs consists of six distinct TF, termed C/EBPα/
β/δ/ɛ/γ/ζ [32]. To unravel which C/EBP family member might control
EGFR expression in A431-KRASG12V cells, SDS-PAGE and immuno-
blot analysis experiments with nuclear protein extracts were performed.
From the six knownC/EBP familymembers, C/EBPβ, C/EBPδ, C/EBPγ,
and C/EBPζ could be detected by immunoblot analysis using specific
primary antibodies (Figure 6A), whereas C/EBPα and C/EBPɛ could
not be detected in these experiments (data not shown). In A431-
KRASG12V cells, the activating isoforms of C/EBPβ, namely liver-
enriched activating proteins (LAP) 1 and 2, were found to be upregulated
when compared with control vector cells. Furthermore, the inhibitory
isoform of C/EBPβ, liver-enriched inhibitory protein (LIP), was exclu-
sively expressed in A431-KRASG12V cells, but not in A431-control-
vector cells—leading to a diminished LAP/LIP ratio (A431-control
vector cells LAP/LIP ratio = 8.9, A431-KRASG12V cells LAP/LIP ratio =
4.4; data determined by densitometric analysis; Figure 6B). Decreased
nuclear expression was found for C/EBPδ in A431-KRASG12V cells
Figure 7. EGFR expression is decreased in KRAS-mutated but not in KRAS wt CRC biopsy samples. (A and B) EGFRmRNA expression in
colonic biopsies from healthy and tumor tissue was determined by real-time PCR. In comparison to biopsies from healthy tissues,
KRAS-mutated CRC sample revealed significant down-regulation of EGFR expression, whereas an increase in EGFR expression was
determined in two of three KRAS wt CRC samples. Means ± SEM are presented from quintuplicates. #P ≤ .05, CRC samples versus
normal colon tissue; *P ≤ .05, no. 5 or 6 versus no. 3 or 4. (C and D) EGFR-IHC on paraffin-embedded colon tumors. Paraffin-embedded
CRC samples (n = 7 KRAS codon 12 mutated; n = 10 KRAS wt) were stained using the EGFR pharmDx kit and evaluated by IHC scoring
(0-300; formula for calculation is depicted in the Materials and Methods section) with parameters as follows: 0 = no staining of cells,
1+ = percentage of cells stained weakly, 2+ = percentage of cells stained moderately, 3+ = percentage of cells stained strongly. Left
y axis = frequency of staining (= percentage of stained cells); right y axis = calculated IHC score. (E) Model of oncogenic KRASG12V
signaling and its impact on the efficiency of EGFR-directed antibodies. In comparison to wt KRAS expressing cells, oncogenic KRASG12V-
expressing cells display strong down-regulation of EGFR expression and decreased activity of the family of C/EBP TF. The family member
C/EBPβ is upregulated by constitutively activated KRASG12V signaling via MAPK p44/42 and could be shown to be involved in EGFR down-
regulation. It might be hypothesized that the induction of the inhibitory isoform C/EBPβ–LIP in KRASG12V-expressing cells is involved in the
suppression of C/EBP TF activity. Because the family of C/EBP TF is involved in the regulation of EGFR promoter activity, suppression of
C/EBP activity is accompanied by down-regulation of EGFR transcription. Hence, decreased expression of EGFR molecules on the cell
surface impairs EGFR-directed Ab-mediated effector mechanisms.
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compared with A431-control-vector cells, whereas no regulation could
be seen for C/EBPγ and C/EBPζ throughout several independent
experiments (Figure 6A). Owing to our observations of strong regula-
tion of C/EBPβ in A431-KRASG12V cells in combination with previous
studies that demonstrated regulation of C/EBPβ activity by RAS signal-
ing pathways [28,29,33], C/EBPβ was selected for further analyses. In
line with these findings, siRNA-mediated knockdown of KRAS4b in
A431-KRASG12V cells for 72 hours induced down-regulation of C/
EBPβ nuclear expression and an increased LAP/LIP ratio (nontransfected
LAP/LIP ratio = 8.8, control siRNA LAP/LIP ratio = 5.5, KRAS4b
siRNA LAP/LIP ratio = 13.8; data determined by densitometric anal-
ysis; data not shown)—confirming a direct association between constitu-
tively activated KRAS and nuclear expression of C/EBPβ (Figure 6C).
Furthermore, siRNA-mediated knockdown of C/EBPβ in A431-
KRASG12V cells led to an increase in LAP/LIP ratio (control siRNA
LAP/LIP ratio = 1.0, C/EBPβ siRNA LAP/LIP ratio = 14.4; data de-
termined by densitometric analysis; data not shown) and to time-
dependent up-regulation of EGFR mRNA (Figure 6D, upper panel)
as well as protein expression (Figure 6E) as also seen in KRAS4b-specific
siRNA knockdown experiments (Figure 4, E and F). Up-regulation of
EGFR mRNA expression by C/EBPβ–specific siRNA knockdown
could be verified in A549 cells, endogenously expressing oncogenic
KRASG12S (Figure 6D, lower panel). Up-regulation of EGFR expression
by C/EBPβ–specific siRNA knockdown was accompanied by signifi-
cantly increased CDC activity in A431-KRASG12V (C/EBPβ siRNA,
lysis rateH425-E3; 1 μg/ml = 12.0% ± 0.9%; control siRNA, lysis
rateH425-E3; 1 μg/ml = 6.5% ± 1.8%) but not in A431-control-vector cells
(Figure 6F ). Enhanced Ab-mediated cytotoxicity could also be ob-
served in C/EBPβ knockdown experiments with the non–small cell
lung carcinoma (NSCLC) cell line A549 as well as with the CRC cell
line HCT-116 (both KRAS mutated; data not shown). To directly link
upregulated EGFR cell surface expression to increased EGFR-Ab–induced
cytotoxicity in A431-KRASG12V cells, human EGFRwas overexpressed in
A431-KRASG12V cells for 24 hours (Figure 6G). After transfection, cells
were analyzed in 51Cr release assays, which revealed a significant increase
in CDC activity only in A431-KRASG12V cells transfected with human
EGFR but not with a mock vector (Figure 6H).
EGFR Expression Is Downregulated in KRAS-Mutated but
Not in KRAS-wt CRC Samples
To support results received from experiments with KRAS-mutated
A431 cells, four CRC biopsy samples and two normal colonic biopsy
samples (Figure 7A) were analyzed by real-time PCR with regard to
EGFR expression. In comparison to normal colonic tissue samples
(nos. 1 and 2), two KRAS-wt expressing CRC samples (nos. 3 and 4)
displayed significantly increased EGFR expression, whereas one KRAS-
wt (no. 5) and one KRAS-mutated (KRAS4bG12Vheterogeneous) CRC sam-
ple (no. 6) displayed significantly decreased EGFR expression (Figure 7,
A and B). Furthermore, immunohistochemical analyses using the US
Food and Drug Administration–approved EGFR pharmDx Kit (Dako)
were performed with KRAS-mutated (only codon 12) and KRAS wt
colorectal carcinoma biopsy samples. Interestingly, a moderate but not
statistically significant trend toward lower EGFR expression in KRAS-
mutated CRC samples (22.43 ± 7.48, n = 7) in comparison to KRAS wt
CRC samples (43.50 ± 26.45, n = 10; Figure 7, C and D) could be
detected. Together, these data suggest that the expression of EGFR in
CRC tissue may be downregulated partially by, for example, oncogenic
mutations such as KRASG12V and suggest an in vivo relevance of our
data observed in stably transfected A431-KRASG12V cells.
Discussion
In patients with colorectal tumors, oncogenic mutations of KRAS
are accompanied by a lack of benefit from therapeutic EGFR-Abs like
cetuximab or panitumumab [6–9]. More recent studies demonstrated
that this negative impact only applies for KRAS codon 12 but not for
codon 13 mutations [34], which was predicted from preclinical stud-
ies demonstrating different functional characteristics of these mu-
tations [35,36]. Here, we systematically investigated underlying
mechanisms of resistance to EGFR antibodies in KRAS-mutated
tumor cells by studying the impact of oncogenic KRASG12V on
Fab- and Fc-mediated effector mechanisms of EGFR-Ab. Interest-
ingly, KRASG12V was found to downregulate EGFR expression by a
C/EBPβ–dependent mechanism.
Activating mutations of KRAS have been demonstrated to over-
come growth inhibition by EGFR antibodies [19]. As we demonstrate
here, stable overexpression of oncogenic KRASG12V was also associ-
ated with impaired Fab- as well as Fc-mediated effector mechanisms
of EGFR-Abs. Hence, CDC-, monocyte-, and PMN-mediated tumor
cell lysis was significantly reduced in KRAS-mutated A431 cells,
whereas NK cell–mediated ADCC was less affected in these cells. This
observation might be explained by findings demonstrating that NK
cell–mediated ADCC activity could be triggered by cetuximab and
zalutumumab at lower EGFR expression, whereas PMN ADCC
and CDC seem to require higher expression levels [37,38]. Reduced
in vitro efficiency of EGFR-mAb in KRAS-mutated cells could be
linked to significant down-regulation of EGFR expression, elicited
by suppressed activity of C/EBP TFs—especially of C/EBPβ. As
siRNA-mediated knockdown of C/EBPβ restored EGFR expression
and thereby enhanced cytotoxic activity against KRAS-mutated cells,
it could be hypothesized that EGFR cell surface expression impacts
the efficiency of EGFR-mAb. Supporting data for oncogenic KRAS
associated down-regulation of EGFR expression were presented in a
recent study where down-regulation of EGFR mRNA expression was
detected in a murine knock-in model for oncogenic KRAS [39]. In
line with these findings, a marked decrease in cell surface expression
of high affinity but not low affinity EGFR was also observed in stably
KRAS4bG12V-transfected human endometrial carcinoma cells [40].
Interestingly, van Houdt et al. [41] analyzed 55 human colorectal
tumor samples for EGFR expression and cellular localization by immuno-
staining. They found a loss of basolateral EGFR localization in 15 of
16 tumor samples positive for KRASmutations. Among these 15 tumor
samples, 5 were negative for EGFR staining. Plasma membrane localiza-
tion of EGFR could be restored in KRAS-mutated cells by Rho kinase
inhibition. These observations strongly suggest that oncogenic KRAS
leads to down-regulation of EGFR expression in vivo, but results from
larger clinical studies need to confirm these results (see next paragraphs).
As shown in the present study, expression of oncogenic KRAS was
accompanied by a strong up-regulation of activating isoforms (LAP) and
the induction of the inhibitory (LIP) isoform of the TF C/EBPβ—leading
to decreased LAP/LIP ratios and subsequently decreased TF activity of
C/EBPβ as well as suppression of EGFR transcription. Decreased LAP/
LIP ratios, thus increased expression of LIP, also have been detected in
tumor tissue samples from breast cancer patients as well as in Duke’s
stage B tumor tissues from CRC patients in comparison to normal tis-
sue samples and have been suggested to be associated with enhanced
tumor invasiveness [42,43]. Previous studies also observed that C/EBPβ
is a nuclear mediator of oncogenic RAS signaling transduction—
promoting cell proliferation and transformation [28,29,44]. Interest-
ingly, other studies found that the inhibitory isoform of C/EBPβ,
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LIP, is overexpressed in human breast cancer and has been shown to be
associated with malignant transformation of epithelial cells [45–47].
Furthermore, when exogenously overexpressed in a human hepatoma
cell line, C/EBPβ–LIP has been shown to suppress transcription in gen-
eral and to be implicated in the induction of prosurvival functions [48].
Although it has been suggested in another study that no CCAAT bind-
ing sites are located in the sequence of the EGFR promoter between
nucleotides −1 to −540 [49], our data show, for the first time, that
the family of C/EBP TF is indeed involved in the regulation of the
EGFR promoter (−620 to −754 nt) activity. Interestingly, EGFR ex-
pression levels were reported to also be downregulated by mechanisms
targeting EGFR for degradation [50,51].
A negative impact of low EGFR expression levels on cetuximab-
triggered NK cell–mediated ADCC activity has previously been
demonstrated in other in vitro studies [27,37,52]. The observation
that NK cell–mediated ADCC was only slightly impaired in A431-
KRASG12V cells when compared with A431-control-vector cells in
the present study may be explained by the fact that, despite of the
significant down-regulation of EGFR expression in A431-KRASG12V
cells, there is still a high cell surface expression of EGFR when com-
pared with other tumor cell lines. Improving antibodies’ Fc-mediated
functions—such as ADCC and CDC—might be a promising approach
to overcome inefficient tumor cell destruction in KRAS-mutated cells.
In previous studies, our group demonstrated in MNC-mediated
ADCC experiments that KRAS-mutated tumor cells, which were resis-
tant to growth inhibition by EGFR-Abs, could be effectively eliminated
by Fc-engineered Ab variants with increased FcγRIIIa binding affinity
[19]. Recently, a phase 1 study with a glycoengineered EGFR-Ab
(GA201) reported clinical responses in patients with KRAS-mutated
tumors—suggesting that KRAS-mediated treatment resistance can
indeed be overcome by improving ADCC efficacy [53].
The impact of EGFR expression levels on the clinical outcome of
EGFR-mAb therapy is controversial. Whereas some studies on CRC
patients did not find a correlation between the extent of EGFR
expression, determined by fluorescent in situ hybridization or IHC,
and the response rate to cetuximab or panitumumab [54,55], other
studies detected a positive correlation [56–59]. Moreover, recent
publications presented data suggesting that, within the population
of mCRCs with wt KRAS, higher response rates to cetuximab-based
treatment were observed in patients with tumors harboring high EGFR
gene copy numbers [60,61]. Furthermore, recent analyses of the phase
III FLEX study in NSCLC revealed a positive impact of high EGFR
expression on the efficiency of chemotherapy plus cetuximab (including
overall survival)—suggesting quantitative EGFR expression by IHC as
a predictive biomarker for cetuximab therapy in NSCLC [62]. To the
best of our knowledge, no data that compare EGFR expression levels by
IHC, depending on the KRAS mutation status, are available.
Taken together, our data, although remaining to be verified in in-
depth analyses using colorectal carcinoma cell line models, provide
novel insights into signaling cascades triggered by oncogenic KRAS
in the context of EGFR-Ab therapy. Besides the induction of prolifer-
ative processes, oncogenic KRAS has been demonstrated to induce ex-
pression of the TF C/EBPβ, especially the dominant-negative isoform
C/EBPβ–LIP, that is implicated in the negative regulation of EGFR
mRNA transcription—resulting in lower EGFR cell surface expression
and impairing Fc-mediated functions of EGFR-Ab (Figure 7). Study-
ing the complex interplay between oncogenic KRAS-associated signal
transduction and EGFR expression provided novel insights into the
resistance mechanisms of tumor cells to EGFR-Abs and suggested
strategies how these antibodies can be optimized to overcome low
EGFR expression in KRAS-mutated tumors.
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Figure W2. KRASG12V-transfected A1207 cells served as a second cell line system. (A) A1207 cells were stably transfected with a vector
for oncogenic KRASG12V and GFP or were left nontransfected. To ensure expression of transfected KRAS, activated RAS was precipi-
tated and analyzed by SDS-PAGE and immunoblot analysis against RAS and Myc-tag (left panel). Whole protein lysates served as ex-
pression control for endogenous RAS and transfected KRASG12V (right panel). (B) Quantitative analyses of EGFR molecules per cell were
performed using QIFIKIT. A1207 cells were incubated with a murine EGFR or control Ab and stained with goat PerCP-conjugated F(ab)2
fragments against murine IgG. Means ± SEM of three independent experiments are presented. Statistical significance was determined
by the Student’s t test. **P ≤ .01.
Figure W1. A431-KRASG12V cells did not display enhanced expres-
sion of complement inhibitors. Quantitative analyses of complement
inhibitor molecules per cell were performed using QIFIKIT. A431-
KRASG12V and A431-control-vector cells were incubated withmurine
CD46 Ab, murine CD59 Ab or murine control Ab and stained with
goat PerCP-conjugated F(ab′)2 fragments against murine IgG.Means
± SEM of three independent experiments are presented. Statistical
significance was determined by the two-way analysis of variance
repeated-measures test with Bonferroni post test. **P ≤ .01.
